Patents Examined by F. C. Eisenschenk
  • Patent number: 5981278
    Abstract: Monoclonal antibodies are revealed which bind to the gp 120 protein on the envelope of HIV-1. These antibodies neutralize HIV-1. They inhibit the rate of infection of T cells, and also inhibit syncytium formation. Further, the antibodies are group-specific and neutralize different strains and isolates of HIV-1. These antibodies have a variety of uses, including the treatment and prevention of AIDS and ARC.
    Type: Grant
    Filed: September 26, 1991
    Date of Patent: November 9, 1999
    Assignee: Tanox, Inc.
    Inventors: Tse-Wen Chang, Michael S. C. Fung, Nancy T. Chang, Bill N. C. Sun, Cecily R. Y. Sun
  • Patent number: 5980884
    Abstract: Methods for the retreatment, using a therapeutically effective amount of interferon consensus, of patients with HCV who exhibit serum ALT values above the upper limit of normal after previous treatment with interferon.
    Type: Grant
    Filed: February 5, 1996
    Date of Patent: November 9, 1999
    Assignee: Amgen, Inc.
    Inventors: Larry Blatt, Michael Klein
  • Patent number: 5871735
    Abstract: The present invention relates to a method of diagnosis of pathological pregnancy which relies on an evaluation of the amount of placental isoferritin (PLF) in the serum or amniotic fluid of a pregnant woman. Diagnosis may also be achieved by observation of percentages of PLF-bearing lymphocytes in the pregnant female. Detection of PLF levels is achieved by immunoassay with a PLF-specific antibody. Also described is a method of treating or preventing pathological pregnancies and transplant or graft rejection by administration of effective amounts of PLF and/or a PLF-specific antibody in combination with immunization.
    Type: Grant
    Filed: June 12, 1990
    Date of Patent: February 16, 1999
    Inventor: Chaya Moroz
  • Patent number: 5424066
    Abstract: A method of increasing the number of CD4+ cells in patients infected with the human immunodeficency virus is provided. The method includes injecting monoclonal antibodies directed against particular antigens on self-reactive, CD4 specific cytotoxic T-cells.
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: June 13, 1995
    Inventor: Allen D. Allen
  • Patent number: 5340923
    Abstract: Antivenoms suitable for treatment of humans and animals as well as for analytical use. A method wherein individual venoms are used to immunize and the resulting antivenoms are, thereafter, purified individually prior to mixing. Immunization is performed in a mammalian or avian host species.
    Type: Grant
    Filed: November 17, 1992
    Date of Patent: August 23, 1994
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventor: Sean B. Carroll
  • Patent number: 5310879
    Abstract: A lipopolysaccharide binding protein, LBP, which is present in acute phase serum of an animal host, but is substantially absent from the normal serum of the host, method of detection, and antibodies that bind to LBP are described.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: May 10, 1994
    Assignee: The Scripps Research Institute
    Inventors: Richard J. Ulevitch, Peter S. Tobias
  • Patent number: 5286850
    Abstract: The subject matter of the present invention relates to bifunctional cyclohexyl DPTA ligands and methods for utilizing these compounds. Antibody DTPA-type ligand conjugates are also provided.
    Type: Grant
    Filed: May 11, 1992
    Date of Patent: February 15, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Otto A. Gansoh, Martin W. Brechbiel
  • Patent number: 5252711
    Abstract: The present invention is concerned with a monoclonal antibody or antigen-binding fragment of a monoclonal antibody produced by a hybridoma formed by fusion of cells from mouse myeloma cells and spleen cells wherein the monoclonal antibody or fragment thereof reacts with the carrier or transfer protein of a bacterial cell. The bacterial cell may be coryneform bacteria or bacteria of the genus Staphylococcus.
    Type: Grant
    Filed: September 27, 1991
    Date of Patent: October 12, 1993
    Assignee: The Gillette Company
    Inventors: Brian Rogers, Anne Maczulak
  • Patent number: 5250666
    Abstract: Chelating compounds of specified structure are useful for radiolabeling targeting proteins such as antibodies. The radiolabeled antibodies, or catabolites thereof, demonstrate improved biodistribution properties, including reduced localization within the intestines.
    Type: Grant
    Filed: November 6, 1992
    Date of Patent: October 5, 1993
    Assignee: NeoRx Corporation
    Inventors: Linda M. Gustavson, Ananthachari Srinivasan, Sudhakar Kasina, Alan R. Fritzberg